Well People Launches Mother's Day Campaign Celebrating 'Pregnancy-Friendly' Beauty for New & Expecting Mothers
This Mother's Day, Well People, a brand from e.l.f. Beauty, is honoring new and expecting moms with the launch of a social media campaign spotlighting its 'Pregnancy-Friendly' designation across the entire Well People product lineup
Share
The 'Pregnancy-Friendly' designation complements the recent achievement of establishing Well People as the color cosmetics brand with the most EWG Verified ® products in the industry. With over 100 products meeting these high standards of 'clean' beauty, Well People continues to set the standard. The EWG Verified ® mark means the products do not contain any ingredients on EWG's list of 'unacceptable' ingredients with health, ecotoxicity and/or contamination concerns.
Pregnancy is a time of change—not just physically, but emotionally and mentally. With so many decisions to make, Well People is helping lighten the load with thoughtful, effective and easy-to-understand beauty and skincare that's pregnancy friendly. The brand knows it isn't just about what's intentionally left out—it's also about what's thoughtfully included. The brand helps eliminates the guesswork during this time of change with formulas free from phthalates, parabens, oxybenzone, phenols, retinoids and more.
'Motherhood is powerful—and so is knowledge,' said Dr. Renée Snyder, Well People co-founder and board-certified dermatologist. 'Our pregnancy-friendly claim empowers expecting moms to feel confident that they're caring for their skin with plant-powered and effective products during such a pivotal stage in life.'
The brand's Mother's Day campaign is part of a broader, always-on approach that continues to highlight beauty routines with expecting mothers in mind. The campaign will also feature real stories from new and expecting mothers across owned social channels. In addition, thoughtful bundles like the 'Glowing Mama Makeup Set' and 'Nurtured Skincare Set' feature hero products like the Fresh Dew Gel-Cream Moisturizer and Juice Cleanse Soothing Aloe Face Cleanser—ideal for expecting mom self-care rituals.
To further amplify this moment and Well People's commitment, the brand will be donating $10,000 to Every Mother Counts, an organization that works to ensure that the maternal health journey before, during, and after childbirth is safe, respectful, and equitable for everyone, everywhere.
To discover all our 'Pregnancy-Friendly' products and explore curated gift sets for Mother's Day, visit www.wellpeople.com
We recommend always checking with a doctor before using any products while pregnant or breastfeeding.
About Well People:
e.l.f. Beauty (NYSE: ELF) is fueled by a belief that anything is e.l.f.ing possible. We are a different kind of company that disrupts norms, shapes culture and connects communities through positivity, inclusivity and accessibility. Well People is a clean beauty pioneer leading the way with high-performing, plant-powered formulas. The brand has the most Environmental Working Group (EWG) Verified ® color cosmetic products of any beauty brand and is committed to be free from sulfates and synthetic fillers. We are Well People clean and vegan, all double-certified by Leaping Bunny and PETA as cruelty free. We are proud to have products made in Fair Trade Certified™ facilities. Learn more at https://www.wellpeople.com/.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
5 hours ago
- Business Wire
Veriheal Expands Patient Support Services With State-Compliant Medical Cannabis Letters
DENVER--(BUSINESS WIRE)--Veriheal, a leading health-tech company specializing in personalized cannabis access, announced this month the expansion of its services to include support beyond certification. The new offerings include state-compliant, physician-signed letters that provide documentation of lawful cannabis use by medical marijuana patients. Veriheal Expands Patient Support Services With State-Compliant Medical Cannabis Letters Veriheal's expanded suite includes medical cannabis letters of necessity and medical diagnosis summaries that confirm lawful marijuana use. These documents are designed to support patients through legal hurdles and assist with applications for employment, insurance, and public programs such as social services. This launch is the first in a series of services reflecting Veriheal's commitment to holistic patient support. The physician-signed letters aim to help patients confidently navigate complex systems while remaining compliant with both federal and state laws. Veriheal will continue the rollout later this year, addressing challenges of medical cannabis use that extend beyond card certification. 'Our patients deserve peace of mind when managing their health,' said Erik Smith, M.D., Medical Director at Veriheal. 'This launch is a foundational step in Veriheal's evolution from a certification provider to a long-term partner in wellness and advocacy.' Available now, patients can request letters to verify legal cannabis use for: Employment and conversations with Human Resources Communications with a parole officer or supervising authority Applications for social services and public programs Documentation of legal possession while driving or on person Supporting state disability paperwork Insurance reimbursement claims or appeals General support for travel or consulting with other medical professionals Each letter is signed by a licensed physician based on the patient's active medical cannabis certification. Patients without a medical cannabis card can access a bundled service to obtain certification and letters of medical necessity. The letters are available digitally on Veriheal's platform and can be requested directly from patients' user portal. For more information, visit About Veriheal Veriheal is a healthcare technology company that facilitates access to medical marijuana cards. As the largest facilitator in the nation, Veriheal advocates for patients and ensures safe access to regulated medical cannabis products. With a commitment to transparency, Veriheal connects patients and physicians through its proprietary, HIPAA-compliant platform. Visit for more information.
Yahoo
5 hours ago
- Yahoo
Jim Cramer Discusses the Uncertainty Around UnitedHealth
UnitedHealth Group Incorporated (NYSE:UNH) is one of the stocks Jim Cramer commented on. When a caller inquired about the company, Cramer said: 'I have long known, this is something I learned probably in my second decade of trading or investing: You do not buy or sell something where you have no idea what is really happening. And at UnitedHealth, there isn't anyone other than the CEO and probably 52,000 lawyers who has any idea what's going on.' Ken Wolter/ UnitedHealth Group Incorporated (NYSE:UNH) provides health benefits, pharmacy care, data analytics, and care delivery services, serving individuals, employers, and public-sector programs. In a July episode, Cramer called the stock 'very, very tricky,' as he remarked: 'UnitedHealth is very, very tricky, and it might be a long-term turn, but I will tell you this, Steve Hemsley is the only person I know who could possibly turn this thing around. Hemsley's back as CEO, he was amazing. I think you have to have fortitude to be in it. I don't like the situation because there's so many winners, as you say, but at least I want people to know that I think Hemsley's is the real deal.' While we acknowledge the potential of UNH as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
5 hours ago
- Business Wire
Spruce Biosciences Announces Integrated Long-Term Clinical Data of Tralesinidase Alfa Enzyme Replacement Therapy (TA-ERT) Demonstrating Profound and Durable Efficacy and Safety in Patients with Sanfilippo Syndrome Type B (MPS IIIB)
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (OTCQB: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced results from a long-term data integration of tralesinidase alfa enzyme replacement therapy (TA-ERT) clinical program in patients with Sanfilippo Syndrome Type B (MPS IIIB). Spruce integrated and evaluated group-level efficacy data for cerebral spinal fluid heparan-sulfate non-reducing end (CSF HS-NRE), cortical grey matter volume (CGMV), and Bayley-III Cognitive Raw Score (BSID-C), the cognitive subscale of the Bayley Scales of Infant and Toddler Development - Third Edition (Bayley-III), as well as safety data over a five-year period from clinical studies 201, 202, and 401. Data from treated patients (n=22) in the studies 201, 202, and 401 was compared with data from untreated patients with MPS IIIB in natural history studies 901 and 902. 'These data demonstrate a rapid, profound, and durable effect of ICV-administered TA-ERT on normalizing CSF HS-NRE, the pathogenic factor leading to neurodegeneration, and in stabilizing CGMV and cognitive function, relative to the declines observed in untreated children with Sanfilippo Syndrome Type B (MPS IIIB) in the natural history studies,' said Paul Harmatz, M.D., Principal Investigator in studies 901, 201, and 202 and Professor in Residence, Department of Pediatrics, University of California, San Francisco (UCSF) and UCSF Benioff Children's Hospital Oakland. 'This is an important development toward relief for children and families whose lives are impacted by this devastating condition.' 'Convincing positive outcomes have been experienced by families who resoundingly state that the benefits of TA-ERT outweigh risks in their real-world experiences,' said Cara O'Neill, M.D., FAAP, Co-Founder and Chief Science Officer of Cure Sanfilippo Foundation. 'Biomarker data, along with promising clinical outcomes, are significant and meaningful from the perspective of the patient community. Currently, there is no U.S. FDA-approved therapy for the treatment of MPS IIIB, and disease management consists of limited palliative care. We are eager to see TA-ERT advance under the accelerated approval pathway.' Cerebral Spinal Fluid Heparan-Sulfate Non-Reducing End (CSF HS-NRE) Integrated group-level data from clinical studies 201, 202, and 401 demonstrate that TA-ERT therapy significantly reduced to normal or near normal CSF HS-NRE levels over a five-year period (Figure 1). At 240 weeks, CSF HS-NRE decreased 91.5 ng/mL from baseline (95% CI: -102.10, -80.90; p<0.0001). Most participants experienced normalization of CSF HS-NRE levels eight weeks after initiating therapy. In a 2024 meeting with the U.S. Food and Drug Administration (FDA), the FDA confirmed that CSF HS-NRE is a surrogate biomarker reasonably likely to predict clinical benefit and could serve as a basis for accelerated approval. Cognitive Function In untreated patients with MPS IIIB, cognitive function peaks at around four years of age and then declines over time. In contrast, children with established disease treated with TA-ERT experienced stable cognitive function over time (Figure 2). Untreated children in the natural history studies showed a decline in cognition beginning at approximately five years of age that progressively worsened over time, while cognition in the TA-ERT treated group remained stable. Using a model-based approach, the mean (95% CI) BSID-C over six to 10 years of age was significantly higher in patients treated with TA-ERT, relative to untreated, age-matched children, with differences evident at six years of age (group difference: 10.67, 95% CI: 3.23, 18.11; p=0.005). At 10 years of age, the difference in BSID-C scores between groups increased to 34.66 (95% CI: 24.38, 44.93; p<0.0001). Although TA-ERT treatment stabilized BSID-C scores on average, increases in BSID-C scores were more commonly observed in subjects who initiated therapy at younger ages with higher baseline cognitive function and prior to the establishment of meaningful neurodegeneration. The BSID-C is anticipated to be the primary endpoint for the post-marketing clinical trial. Cortical Grey Matter Volume (CGMV) TA-ERT therapy was also associated with stabilization of CGMV, relative to the decline in CGMV observed in untreated children due to the progressive neurodegenerative nature of MPS IIIB (Figure 3). While CGMV should increase with age in children up to five years of age, there was an average loss of ~32 mL over 48 weeks in untreated children with MPS IIIB observed in study 901. Consistent with TA-ERT's mechanism of action, decreases in CGMV were observed during the initial 24 weeks of TA-ERT treatment, likely reflecting intracellular clearance of cerebral spinal fluid heparan sulfate (CSF HS) and CSF HS-NRE. CGMV stabilized from weeks 48 to 240 with TA-ERT treatment. Safety TA-ERT therapy exposure for up to 7.3 years has demonstrated an adequate safety profile in a serious and fatal disease for which no treatment is currently available. The mean (SD) exposure to TA-ERT was 4.2 (2.0) years. No deaths occurred throughout study 201 and its long-term extension studies 202 and 401. The most frequent treatment-emergent adverse event (TEAE) by preferred term (reported in ≥40% of participants) was vomiting (22 [100%]), followed by pyrexia (20 [90.9%]), upper respiratory tract infection (17 [77.3%]), pleocytosis (11 [50.0%]), COVID-19 infection (10 [45.5%]), and diarrhea (9 [40.9%]). Four (18%) patients discontinued treatment, although three (14%) discontinuations were due to hydrocephalus, a known complication of MPS IIIB. Adverse events related to the ICV device were consistent with other therapies administered by the ICV route. About Sanfilippo Syndrome Type B (MPS IIIB) MPS IIIB is an ultra-rare, serious, and fatal genetic disease characterized by deficiency in N-Acetyl-Alpha-Glycosaminidase (NAGLU), an enzyme required for the catabolism of heparan sulfate (HS) in lysosomes. It is estimated that MPS IIIB affects fewer than 1:200,000 people in the United States (U.S.), but the true incidence and prevalence are difficult to ascertain because MPS IIIB is a disease currently not included in newborn screening. The accumulation of toxic levels of cerebral spinal fluid heparan sulfate in the brain is the underlying pathophysiology of MPS IIIB. Although signs and symptoms of MPS IIIB can vary amongst affected individuals, progressive neurodegeneration typically follows a predictable path to brain atrophy, cognitive and developmental impairment, hyperactivity with aggressive and destructive behavior, delayed speech, hearing loss, and motor skill deficits. Somatic manifestations include coarse facial features, hepatosplenomegaly, and gastrointestinal symptoms. The final stage of MPS IIIB is typically marked by severe dementia, loss of motor function, and seizure activity, with patients largely bed-ridden and requiring constant care, requiring feeding tubes for hydration and nutrition, and ultimately leading to death. The estimated life expectancy of individuals with MPS IIIB ranges from 15 to 19 years of age. Currently, there are no FDA-approved therapies for MPS IIIB, and management of the disease consists of limited palliative care to improve quality of life. About Tralesinidase Alfa Enzyme Replacement Therapy (TA-ERT) Tralesinidase Alfa Enzyme Replacement Therapy (TA-ERT) is a fusion protein comprised of recombinant human alpha-N-acetylglucosaminidase (rhNAGLU). TA-ERT is intended as an enzyme replacement therapy for the treatment of patients with MPS IIIB (Sanfilippo Syndrome Type B) who lack rhNAGLU enzyme activity. TA-ERT is expected to restore rhNAGLU enzyme activity in the central nervous system following intracerebroventricular injection. rhNAGLU typically lacks the mannose-6-phosphate residues that are essential for efficient cellular uptake via the M6P receptor pathway. As a result, the naked enzyme is poorly absorbed by cells, including neurons. To address this challenge, TA-ERT is fused to an insulin-like growth factor 2 peptide, which binds to the cation-independent mannose-6-phosphate on cell surfaces. This fusion enables the enzyme to be internalized and delivered to the lysosome, thereby enhancing its therapeutic potential for treating MPS IIIB. By restoring NAGLU enzymatic activity and promoting clearance of lysosomal heparan sulfate and heparan sulfate non-reducing end in the brain, TA-ERT therapy is expected to preserve neuronal cell health and potentially halt or slow the neurological decline and improve clinical outcomes in affected patients. TA-ERT has been evaluated in three clinical studies in participants with MPS IIIB: the interventional study 201 and extension studies 202 and 401. Twenty-two individuals with MPS IIIB have been administered TA-ERT therapy. TA-ERT has demonstrated an adequate safety profile based on integrated five years of safety data. About Spruce Biosciences Spruce Biosciences is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need. To learn more, visit and follow us on X, LinkedIn, Facebook and YouTube. Forward-Looking Statements Statements contained in this press release regarding matters that are not historical facts are 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements regarding, among other things, the ability to seek accelerated approval of TA-ERT for MPS IIIB based on existing clinical data. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as 'anticipate', 'will', 'potential', 'intend', 'expect' and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Spruce's current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks and uncertainties associated with Spruce's business in general, the impact of geopolitical and macroeconomic events, and the other risks described in Spruce's filings with the U.S. Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management's assumptions and estimates as of such date. Spruce undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.
